Natera, Inc. NASDAQ:NTRA Executive Chairman Matthew Rabinowitz sold 22,900 shares of common stock on November 4, 2025, for approximately $4.59 million. The transaction comes as Natera's stock trades near its 52-week high of $203.22, having delivered an impressive 57.93% return over the past year.
The sales were executed in two separate transactions. In the first transaction, 17,198 shares were sold at a weighted average price of $200.2887, for a total value of $3444585. The price per share in this transaction ranged from $200.00 to $200.74. In the second transaction, 5,702 shares were sold at a weighted average price of $201.1766, for a total value of $1147089 with prices ranging from $201.01 to $201.38 per share.
Following these transactions, Rabinowitz directly owns 2,280,852 shares of Natera common stock. An additional 5,000 shares are indirectly owned by a spouse.
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by Rabinowitz on June 13, 2025. Investors should note that Natera, currently valued at $26.99 billion, is scheduled to release earnings on November 6, just one day away. According to InvestingPro data, analysts maintain a bullish consensus on the stock with price targets ranging from $172 to $235. For deeper insights into Natera's financial health and growth prospects, InvestingPro offers 14 additional tips and a comprehensive Pro Research Report.
In other recent news, Natera has reported new results from its early cancer detection program, specifically targeting advanced adenomas, which are precancerous polyps that can lead to colorectal cancer. The company's PROCEED-CRC clinical trial revealed a blood-based screening test with 22.5% sensitivity and 91.5% specificity for detecting these advanced adenomas. Meanwhile, Piper Sandler has reiterated an Overweight rating for Natera, maintaining a $220 price target due to the company's strong position in the molecular diagnostics space. Canaccord Genuity also maintained its Buy rating with a $200 price target, citing Natera's effective use of its Signatera test in guiding treatment for muscle-invasive bladder cancer. Additionally, BTIG raised its price target for Natera to $210, following positive clinical trial results in the same area. These developments underscore Natera's continuing advancements in cancer diagnostics and treatment guidance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.